Based on the recent earnings call, it is recommended to take an "overweight" investment stance on Amgen Inc. The company has demonstrated strong and continued volume growth on multiple products, such as Prolia, Repatha, KYPROLIS, and BLINCYTO. With an exceptional performance by Prolia, a robust volume growth by Repatha, and a unique position in a competitive myeloma market by KYPROLIS, the company has shown promising results. Additionally, upcoming launches in 2018, including biosimilar products and new device launches, are expected to contribute to future growth. Furthermore, the company's successful negotiations and expected net selling price trends indicate a positive outlook for the future. In conclusion, Amgen Inc. appears to be well-positioned for growth and presents a compelling investment opportunity.